Screening for Lung Cancer in the HIV Patient

HIV 患者的肺癌筛查

• 批准号: 7115021
• 负责人: MALCOLM V BROCK
• 金额: $ 14.01万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7115021
• 关键词: DNA methylation; HIV infections; bioimaging /biomedical imaging; cancer registry /resource; cancer risk; clinical research; computed axial tomography; early diagnosis; gene environment interaction; high risk behavior /lifestyle; human subject; lung imaging /visualization /scanning; lung neoplasms; mass screening; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer genetics; patient oriented research; serum; smoking; sputum; tissues; tobacco abuse

DESCRIPTION (provided by applicant): Preliminary data from HIV-seropositive patients at Johns Hopkins demonstrate a high rate of death from lung cancer. We derived 87 cases of HIV-seropositive patients with lung cancer who had been treated at the institution. Almost all patients were young (median age 46 years), African-American males from inner city Baltimore with a strong history of cigarette smoking. The prevalence of smoking was 97%, with 89% being current smokers. Despite patients being carefully followed for their HIV disease, only 4.6% of the HIV-positive lung cancer patients initially presented with stage 1 disease, and only 11 patients (13%) were able to undergo surgery. Over the past 5 years, six large-scale computed tomography (CT) lung cancer screening trials of 18,387 patients at high risk for lung cancer have been published. Of 140 lung cancers detected, 79% (110/140) had stage 1 disease. This contrasts with 24% of patients presenting with stage 1 lung cancer patients without CT screening. This suggests that CT screening is sensitive in detecting small, early stage lung cancer. We hypothesize that CT screening of heavy HIV-seropositive smokers will detect a higher proportion of stage 1 lung cancers than are currently being detected. This project is a prospective cohort study that will enroll 200 HIV-seropositive smokers who have current or previous smoking history of at least 20 pack years. We anticipate 18 lung cancers in the first year alone. Specific aim 1 addresses if differences in stage distribution of HIV-positive patients at lung cancer diagnosis can be determined between those HIV-positive heavy smokers who are screened by spiral CT and historical controls. Our second specific aim focuses on the establishment of a specimen bank of serum, sputum, and tissue from these screened HIV-positive smokers. Our third specific aim is to use epigenetic analysis of sera and sputa collected in Specific Aim 2 as a complementary approach to low dose helical CT in order to discriminate radiologically indeterminate nodules as either molecularly positive or negative.

描述（由申请人提供）：来自约翰霍普金斯的HIV血清阳性患者的初步数据表明肺癌的死亡率很高。我们来自87例艾滋病毒血清阳性肺癌患者谁曾在该机构接受治疗。几乎所有患者均为年轻（中位年龄46岁），来自市中心巴尔的摩的非裔美国男性，有强烈的吸烟史。吸烟率为97%，其中89%为当前吸烟者。尽管对患者的HIV疾病进行了仔细的随访，但只有4.6%的HIV阳性肺癌患者最初表现为1期疾病，只有11名患者（13%）能够接受手术。在过去的5年中，已经发表了6项针对18，387名肺癌高危患者的大规模计算机断层扫描（CT）肺癌筛查试验。在检测到的140例肺癌中，79%（110/140）为1期疾病。这与24%的1期肺癌患者没有CT筛查形成鲜明对比。这表明CT筛查在检测小的早期肺癌方面是敏感的。我们假设，对HIV血清阳性的重度吸烟者进行CT筛查，将比目前检测到的1期肺癌比例更高。该项目是一项前瞻性队列研究，将招募200名HIV血清阳性吸烟者，他们目前或以前的吸烟史至少为20包年。我们预计仅在第一年就有18例肺癌。具体目标1解决了是否可以确定通过螺旋CT筛查的HIV阳性重度吸烟者与历史对照之间在肺癌诊断时HIV阳性患者的分期分布差异。我们的第二个具体目标是建立一个样本库的血清，痰，和组织从这些筛选艾滋病毒阳性吸烟者。我们的第三个具体目标是使用表观遗传学分析的血清和特异性目标2中收集的血清作为低剂量螺旋CT的补充方法，以区分放射学上不确定的结节，无论是分子阳性或阴性。